There are three products currently in clinical trials that would probably interest you.

First is Acorda's CVT-301, which is a self-administered, inhaled levodopa therapy. The drug is now about half-way though several phase 3 studies with a possible NDA being filed late this year or early next year (more probable). The early results, and the phase 2 results, were all very good. It is very quick acting and has shown minimal side effects. However, at this time, it is only being tested as a "rescue-drug" for serious off periods and not for general use. I've seen the inhaler and found it a little clumsy, but still something that could be used by most patients without assistance.

Second is Cynapsus Therapeutic's APL-130277, is an which is an easy-to-administer, sublingual thin film formulation of apomorphine. When patients are OFF or begin to experience the onset of an OFF episode, they simply peel open the packaging, remove the thin film and place it under their tongue. The thin film dissolves over the course of a few minutes, allowing the apomorphine to enter into the bloodstream quickly. Cynapasus has just begun phase 3 trials and there are multiple centers across the US which will begin recruitment shortly. As with CVT, the early results have been very positive.

Third, and most closely to what you were asking about, would ne NeuroDerm's ND0612L and ND0612H. ND0612L is administered subcutaneously through a convenient, small belt-worn pump similar to the administration devices used to deliver insulin to diabetic patients. A second generation product, using a patch pump to deliver LD/CD, is under development. NeuroDerm has just begun the recruitment for a phase 2 efficacy trial.

I would highly anticipate that CVT and APL will both have successful phase 3 trials and receive FDA approval. I would anticipate they would be available by 2018, if not sooner.